サンバイオの株価時系列
| 日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
|---|---|---|---|---|---|---|---|
| 2022/03/31 | 1,194 | 1,212 | 1,175 | 1,205 | +6 | +0.5% | 612,900 |
| 2022/03/30 | 1,224 | 1,224 | 1,182 | 1,199 | -6 | -0.5% | 616,700 |
| 2022/03/29 | 1,225 | 1,228 | 1,194 | 1,205 | -17 | -1.4% | 749,800 |
| 2022/03/28 | 1,280 | 1,280 | 1,221 | 1,222 | -64 | -5% | 609,100 |
| 2022/03/25 | 1,283 | 1,290 | 1,262 | 1,286 | -18 | -1.4% | 554,700 |
| 2022/03/24 | 1,310 | 1,328 | 1,261 | 1,304 | -9 | -0.7% | 986,900 |
| 2022/03/23 | 1,322 | 1,347 | 1,313 | 1,313 | -3 | -0.2% | 631,900 |
| 2022/03/22 | 1,366 | 1,373 | 1,303 | 1,316 | -77 | -5.5% | 1,014,400 |
| 2022/03/18 | 1,381 | 1,435 | 1,374 | 1,393 | +15 | +1.1% | 1,003,800 |
| 2022/03/17 | 1,363 | 1,383 | 1,314 | 1,378 | +37 | +2.8% | 1,086,600 |
| 2022/03/16 | 1,400 | 1,464 | 1,321 | 1,341 | -59 | -4.2% | 1,347,800 |
| 2022/03/15 | 1,367 | 1,424 | 1,341 | 1,400 | +5 | +0.4% | 803,800 |
| 2022/03/14 | 1,336 | 1,452 | 1,336 | 1,395 | -131 | -8.6% | 1,354,800 |
| 2022/03/11 | 1,505 | 1,555 | 1,475 | 1,526 | -45 | -2.9% | 1,312,200 |
| 2022/03/10 | 1,613 | 1,641 | 1,526 | 1,571 | +13 | +0.8% | 1,366,600 |
| 2022/03/09 | 1,740 | 1,740 | 1,502 | 1,558 | -211 | -11.9% | 2,570,100 |
| 2022/03/08 | 2,022 | 2,182 | 1,750 | 1,769 | -188 | -9.6% | 5,254,500 |
| 2022/03/07 | 1,932 | 1,983 | 1,866 | 1,957 | -82 | -4% | 1,259,400 |
| 2022/03/04 | 2,110 | 2,116 | 1,995 | 2,039 | -120 | -5.6% | 1,752,800 |
| 2022/03/03 | 2,196 | 2,220 | 2,114 | 2,159 | -19 | -0.9% | 2,038,200 |
| 2022/03/02 | 2,068 | 2,200 | 1,927 | 2,178 | +101 | +4.9% | 2,776,600 |
| 2022/03/01 | 1,899 | 2,126 | 1,874 | 2,077 | +214 | +11.5% | 3,337,700 |
| 2022/02/28 | 1,622 | 1,863 | 1,616 | 1,863 | +216 | +13.1% | 2,338,500 |
| 2022/02/25 | 1,601 | 1,666 | 1,578 | 1,647 | +86 | +5.5% | 1,222,600 |
| 2022/02/24 | 1,648 | 1,663 | 1,545 | 1,561 | -84 | -5.1% | 1,716,900 |
| 2022/02/22 | 1,510 | 1,670 | 1,510 | 1,645 | +87 | +5.6% | 2,793,400 |
| 2022/02/21 | 1,381 | 1,566 | 1,351 | 1,558 | +129 | +9% | 1,997,700 |
| 2022/02/18 | 1,402 | 1,499 | 1,386 | 1,429 | -44 | -3% | 1,627,300 |
| 2022/02/17 | 1,600 | 1,602 | 1,411 | 1,473 | -173 | -10.5% | 2,326,900 |
| 2022/02/16 | 1,700 | 1,758 | 1,560 | 1,646 | -39 | -2.3% | 6,966,400 |
| 2022/02/15 | 1,685 | 1,685 | 1,685 | 1,685 | +300 | +21.7% | 213,700 |
| 2022/02/14 | 1,385 | 1,385 | 1,385 | 1,385 | +300 | +27.6% | 78,400 |
| 2022/02/10 | 1,101 | 1,132 | 1,082 | 1,085 | -13 | -1.2% | 369,500 |
| 2022/02/09 | 1,117 | 1,122 | 1,079 | 1,098 | +4 | +0.4% | 205,700 |
| 2022/02/08 | 1,100 | 1,117 | 1,089 | 1,094 | -7 | -0.6% | 186,400 |
| 2022/02/07 | 1,097 | 1,118 | 1,087 | 1,101 | +4 | +0.4% | 217,600 |
| 2022/02/04 | 1,120 | 1,133 | 1,077 | 1,097 | -12 | -1.1% | 368,900 |
| 2022/02/03 | 1,100 | 1,111 | 1,084 | 1,109 | -7 | -0.6% | 315,500 |
| 2022/02/02 | 1,094 | 1,127 | 1,090 | 1,116 | +45 | +4.2% | 265,400 |
| 2022/02/01 | 1,081 | 1,103 | 1,056 | 1,071 | -12 | -1.1% | 262,800 |
| 2022/01/31 | 1,036 | 1,092 | 1,036 | 1,083 | +43 | +4.1% | 329,300 |
| 2022/01/28 | 1,080 | 1,097 | 1,017 | 1,040 | -29 | -2.7% | 312,200 |
| 2022/01/27 | 1,124 | 1,140 | 1,057 | 1,069 | -27 | -2.5% | 340,600 |
| 2022/01/26 | 1,052 | 1,115 | 1,052 | 1,096 | +41 | +3.9% | 275,800 |
| 2022/01/25 | 1,139 | 1,145 | 1,047 | 1,055 | -56 | -5% | 463,300 |
| 2022/01/24 | 1,095 | 1,120 | 1,075 | 1,111 | -10 | -0.9% | 299,100 |
| 2022/01/21 | 1,168 | 1,179 | 1,115 | 1,121 | -71 | -6% | 388,600 |
| 2022/01/20 | 1,193 | 1,223 | 1,167 | 1,192 | -16 | -1.3% | 340,800 |
| 2022/01/19 | 1,250 | 1,253 | 1,199 | 1,208 | -45 | -3.6% | 366,400 |
| 2022/01/18 | 1,255 | 1,295 | 1,242 | 1,253 | +3 | +0.2% | 338,800 |
751～
800
件表示中 / 2454件
類似銘柄と比較する
現在ご覧いただいている「サンバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
| 銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
|---|---|---|---|---|---|---|---|---|
| サンバイオ | 208,800円 | - | - | 0.00% | - | 96.71倍 |
|
脳疾患向け再生細胞薬の開発・製造・販売目指すバイオベンチャー。米国で創業し日本に逆上陸 |
| 科研薬 | 413,300円 | +30.5% | +111.0% | 4.60% | 11.65倍 | 1.01倍 |
|
旧理研グループの名門。導入の関節機能改善剤、自社創製の爪白癬症薬の２本柱。後発品も展開 |
| キッセイ薬 | 384,500円 | +14.5% | -2.3% | 2.34% | 14.07倍 | 0.75倍 |
|
医薬品中堅。泌尿器、腎・透析、未充足医療が重点領域。主軸特許切れ、新しい柱育成。海外は導出 |
| 東和薬品 | 259,400円 | +15.0% | -7.3% | 2.70% | 8.51倍 | 0.80倍 |
|
後発医薬品メーカーで国内２強の一角。循環器系に強い。直販軸に発展も卸との取引を拡大中 |
| 鳥居薬 | 451,000円 | +7.1% | -35.0% | 2.66% | 37.29倍 | 1.04倍 |
|
ＪＴ傘下。柱の抗ＨＩＶ薬販売権喪失後、自社製品の腎・透析、アレルゲン等の開発強化 |
市場注目の銘柄
チャート関連のコラム
